The anti-inflammatory and immune-modulatory effects of OEA limit DSS-induced colitis in mice
Laboratory studyOther animalsWith oleoylethanolamide (OEA, a related lipid, tested alone; PEA was not given)
This study tested palmitoylethanolamide together with oleoylethanolamide (OEA, a related lipid, tested alone; PEA was not given). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- C57BL/6J mice given 2.5% dextran sodium sulphate in drinking water for 5 days (numbers not stated in the abstract)
- Dose used in the study
- OEA 10 mg/kg intraperitoneally daily, starting 3 days before DSS
- Duration
- 12 days
- What was measured
- Colitis disease score; colonic PPAR-alpha, tight junction and protective factor mRNA; colonic and systemic cytokines; TLR4, NF-kappa-B, MyD88 and NLRP3 pathways; cytokines in mesenteric lymph nodes.
What the authors reported
The study found:
- OEA improved disease score, restored PPAR-alpha, tight junction and protective factor transcription, and lowered colonic and systemic pro-inflammatory cytokines.
- The authors attribute the effect to TLR4 axis targeting with downstream NF-kappa-B and NLRP3 inhibition.
- OEA also blocked the cytokine rise in mesenteric lymph nodes.
Limits of this study
A mouse colitis model of OEA, not palmitoylethanolamide; PEA is mentioned only as the better-known comparator. It cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 32559625 · doi:10.1016/j.biopha.2020.110368
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.